Clinical trials: Vasomotor Symptoms
Postmenopausal Symptoms, Menopause
Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)
To investigate efficacy and safety of 4 doses of esmirtazapine, compared to placebo, in the treatment of moderate to severe hot flushes (vasomotor symptoms) associated with the menopause.
- Conditions
- Postmenopausal Symptoms, Menopause, Vasomotor Symptoms
- Trial name
- NCT00535288
- Testing
- Esmirtazapine
- Volunteers
- 946 people
- Sponsor
- Merck Sharp & Dohme LLC
Menopause, Hot Flashes
Gabapentin for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women
The broad goal of this study is to obtain pilot data to determine the tolerability and preliminary efficacy of the non-hormonal agent gabapentin for insomnia symptoms and nighttime vasomotor Symptoms (VMS) when open-label…
- Conditions
- Menopause, Hot Flashes, Vasomotor Disturbance
- Trial name
- NCT02040532
- Testing
- Gabapentin
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital
Hot Flashes, Prostate Cancer
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
RATIONALE: Soy protein/isoflavones and venlafaxine may help relieve hot flashes in patients receiving hormone therapy for prostate cancer.
- Trial name
- NCT00354432
- Testing
- oral soy protein/isoflavones powder, Venlafaxine
- Where
- 20 sites in United States
- Volunteers
- 120 people
- Sponsor
- Wake Forest University Health Sciences
Hot Flashes
A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2
This study was for women in menopause with moderate to severe hot flashes. Menopause, a normal part of aging, is the time of a woman's last period. Hot flashes can interrupt a woman's daily life.
- Trial name
- Skylight 2 (NCT04003142)
- Testing
- Fezolinetant
- Where
- 93 sites in United States, Canada and 5 more
- Volunteers
- 501 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Menopause
Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients
The purpose of this study is to assess the safety and effectiveness of S-equol in menopausal patients with hot flushes and night sweats.
- Trial name
- NCT00962585
- Testing
- S-equol
- Where
- 9 sites in United States, Australia
- Volunteers
- 169 people
- Sponsor
- Ausio Pharmaceuticals, LLC
Vasomotor Symptoms Associated With Menopause, Hot Flashes
A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause
Researchers are looking for a better way to treat women who have hot flashes after women have been through the menopause. Hot flashes are caused by the hormonal changes that happen when a woman's body has been through the…
- Trial name
- OASIS-1 (NCT05042362)
- Testing
- Elinzanetant (BAY3427080)
- Where
- 99 sites in United States, Austria and 6 more
- Volunteers
- 396 people
- Sponsor
- Bayer
Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
Researchers are looking for a better way to treat women with, or at high risk for developing hormone-receptor positive breast cancer, who have vasomotor symptoms (VMS), a condition of having hot flashes caused by anti-cancer…
- Trial name
- OASIS-4 (NCT05587296)
- Testing
- Elinzanetant (BAY3427080)
- Where
- 102 sites in Austria, Belgium and 14 more
- Volunteers
- 474 people
- Sponsor
- Bayer
Postmenopausal Symptoms
Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women
The purpose of this study is to assess the pharmacokinetics (absorption, breakdown and elimination from the body), safety and tolerability of Brisdelle (paroxetine mesylate) Capsules 7.5 mg when given as a single dose and…
- Trial name
- N30-005 (NCT01829919)
- Testing
- Brisdelle (paroxetine mesylate)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Noven Therapeutics
Severe Vasomotor Symptom Associated With Menopause
Post Marketing Surveillance To Observe Safety And Efficacy Of Duavive
To evaluate safety and efficacy of CE/BZA in real practice in Korea
- Trial name
- NCT02792504
- Where
- 20 sites in South Korea
- Volunteers
- 669 people
- Sponsor
- Pfizer
Menopausal and Female Climacteric States
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
The purpose of this study is to determine whether GSK232802 is safe and effective in reducing the frequency and severity of hot flashes associated with menopause.
- Trial name
- NCT00604825
- Testing
- GSK232802, PREMARIN
- Where
- 87 sites in United States, Argentina and 7 more
- Volunteers
- 356 people
- Sponsor
- GlaxoSmithKline
Depression, Menopause
Duloxetine for Menopausal Depression
The primary objective of the study is to determine if an eight-week intervention with duloxetine significantly reduces depressive symptoms in symptomatic menopausal women.
- Conditions
- Depression, Menopause, Vasomotor Symptoms
- Trial name
- NCT01117857
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Massachusetts General Hospital
Hot Flashes
Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms
Estradiol treatment is effective at reducing vasomotor symptoms (eg hot flushes) in postmenopausal women. This study will evaluate the safety and efficacy of Evamist.
- Trial name
- NCT01389102
- Testing
- Estradiol transdermal one 90 μL spray, Estradiol transdermal spray, two 90 μL sprays, Estradiol transdermal three 90 μL sprays
- Where
- 43 sites in United States
- Volunteers
- 454 people
- Sponsor
- Lumara Health, Inc.
Vasomotor Symptoms; Hot Flashes
Study of Erenumab (AMG 334) in Women With Hot Flashes
The primary objective of this study was to evaluate the frequency of moderate to severe daily hot flashes 4 weeks after a single dose of erenumab (AMG 334) in women with hot flashes associated with menopause.
- Trial name
- NCT01890109
- Testing
- Erenumab
- Where
- 7 sites in United States
- Volunteers
- 103 people
- Sponsor
- Amgen
Hot Flashes, Menopause
MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms
The primary objective of this study is to determine the efficacy of both low-dose oral (by mouth) 17-ß-estradiol and the non-hormonal drug venlafaxine XR compared to placebo in reducing hot flashes.
- Conditions
- Hot Flashes, Menopause, Vasomotor Disturbance
- Trial name
- NCT01418209
- Testing
- Low-dose 17-ß-estradiol with progesterone taper, Venlafaxine XR
- Where
- 4 sites in United States
- Volunteers
- 339 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Postmenopausal Symptoms
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
The purpose of this study is to assess the safety \& efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause.
- Trial name
- N30-003 (NCT01361308)
- Testing
- Brisdelle (paroxetine mesylate)
- Where
- 74 sites in United States
- Volunteers
- 614 people
- Sponsor
- Noven Therapeutics
Hot Flashes, Menopause
MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women
The purpose of this study is to test whether a medication reduces the number, severity and bothersomeness of menopausal hot flashes. Escitalopram (also called Lexapro®) is a selective serotonin reuptake inhibitor (SSRI).
- Conditions
- Hot Flashes, Menopause, Vasomotor Symptoms
- Trial name
- NCT00894543
- Testing
- Escitalopram
- Where
- 5 sites in United States
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Hot Flashes
A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause
This study was for women in menopause with hot flashes. Menopause, a normal part of aging, was the time of a woman's last period. Hot flashes can interrupt a woman's daily life.
- Trial name
- Skylight 4 (NCT04003389)
- Testing
- fezolinetant
- Where
- 182 sites in United States, Canada and 6 more
- Volunteers
- 1,831 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Depression, Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied in the development program for the treatment of…
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00369343
- Testing
- Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)
- Where
- 37 sites in United States
- Volunteers
- 381 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Moderate to Severe Vasomotor Symptoms in Postmenopausal, Women
A Study of MK-6913 for the Treatment of Hot Flashes in Postmenopausal Women (6913-004)
This study will assess the safety, tolerability, and efficacy of MK-6913 for the treatment of moderate-to-very-severe vasomotor symptoms (hot flashes or hot flushes) in postmenopausal women.
- Trial name
- NCT01015677
- Testing
- MK-6913, 17-β estradiol, MK-6913 25 mg
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Endothelial Dysfunction, Obesity
Leptin Infusion and Endothelial Vasomotor Response
Adipose tissue is an active endocrine organ producing several hormones with circulatory and metabolic effects. In 1994, the hormone leptin was discovered.
- Conditions
- Endothelial Dysfunction, Obesity, Vasodilation, Venous Occlusion Plethysmography
- Trial name
- LIVARM (NCT04374500)
- Testing
- Leptin infusion plus vasodilators in healthy men, Leptin infusion in healthy men, Vasodilators in CAD patients
- Where
- 2 sites in Sweden, United Kingdom
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Stefan Soderberg